Pneumovax is a vaccine that prevents the development of Streptococcus pneumoniae or S. pneumoniae, the most common cause of pneumonia. This microorganism can also cause severe infections in the blood and brain. Pneumovax is the brand name for one of the vaccines that protect against S. pneumonaie; It contains 23 proteins of the most common types of bacteria, and is recommended for adults over 65 years. The other, Prevnar, contains 13 varieties of the S. pneumonaie protein and is a vaccine routinely administered during childhood.
Pneumovax is recommended for elderly patients because the infection and its complications are more common in older adults. Individuals with compromised immune systems due to human immunodeficiency virus, lack of a vessel, organ transplant, cancer or medication should also receive the vaccine, as well as adults between the ages of 19 and 64 who smoke or they suffer from alcoholism, diabetes or a chronic disease of the lungs, heart, liver or kidneys. Adults over 65 who have an average risk of developing S. pneumoniae require only one dose of the vaccine, while members of high-risk groups should receive a second dose five or more years after the first.
Although doctors do not routinely recommend Pneumovax in pregnant women who are not at high risk of contracting pneumonia, some research shows that pregnant women who have received the vaccine can transfer immunity to the fetus or young children through the breastmilk. Pneumovax should not be administered to individuals who are severely ill or who had an allergic reaction to a previous dose.
Prevnar is a vaccine routinely administered during infancy to babies 12 to 15 months of age and children of 2, 4, and 6 years. The vaccine is administered at such an early age because pneumococcal disease is more common in children under 2 years of age. S. pneumoniae is the leading cause of disease and death in children worldwide. Death due to pneumococcal infections is more common in developing countries because the vaccine is not available. In the United States, invasive pneumococcal diseases in children have decreased by 74% since 1997, when the vaccine was introduced, until 2008.
The most common side effects of Pneumovax and Prevnar are redness and swelling where the vaccine was injected. vaccine. One percent of people who receive the vaccine suffer from fever and muscle pain. Serious reactions to vaccines are extremely rare.